by MM360 Staff | Jul 25, 2025 | Publications
Rofo. 2025 Jul 23. doi: 10.1055/a-2625-5643. Online ahead of print. ABSTRACT Multiple myeloma (MM) is the second most common hemato-oncological malignancy, characterized by the clonal proliferation of malignant plasma cells and bone marrow infiltration. The degree of...
by MM360 Staff | Jul 22, 2025 | Publications
J Geriatr Oncol. 2025 Jul 19;16(7):102321. doi: 10.1016/j.jgo.2025.102321. Online ahead of print. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is an incurable blood cancer with improved survival rates due to advances in treatment, including stem cell transplantation,...
by MM360 Staff | Jul 15, 2025 | Publications
Surg Neurol Int. 2025 Jun 20;16:247. doi: 10.25259/SNI_249_2025. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) typically affects the bone marrow. When it spreads to the central nervous system, it usually presents as intracranial metastasis or extradural...
by MM360 Staff | Jul 13, 2025 | Publications
Clin Nucl Med. 2025 Jul 8. doi: 10.1097/RLU.0000000000006048. Online ahead of print. ABSTRACT PURPOSE: This systematic review and meta-analysis compared the diagnostic performance of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI in detecting focal bone lesions and bone...
by MM360 Staff | Jul 4, 2025 | Publications
Leukemia. 2025 Jul 2. doi: 10.1038/s41375-025-02677-5. Online ahead of print. ABSTRACT The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis...
by MM360 Staff | Jun 27, 2025 | Publications
Cancers (Basel). 2025 Jun 11;17(12):1943. doi: 10.3390/cancers17121943. ABSTRACT Background: Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to standard first-line triplet regimens, including a proteasome inhibitor (PI), an immunomodulatory drug...
